Hepatitis/MASH

Specific blood-born microRNAs mutate before the development of hepatocellular carcinoma.

Liver cancer cells died when the AURKA-MYC interaction was inhibited.

Top news of the day from across the health care landscape.

While cancer spending contributes largely to medical spending, it only accounted for 6.3% of growth from 2000 to 2012.

Epclusa is the first drug approved to treat all 6 major genotypes of hepatitis C virus.

Epclusa showed up to 99% viral suppression after 12 weeks across major hepatitis C genotypes.

Some injection drug users with HIV and hepatitis C seem to have the same immune problems as the elderly.

The FDA today approved Gilead Sciences' sofosbuvir and velpatasvir (Epclusa) for the treatment of adult patients with chronic hepatitis C virus both with and without cirrhosis.

Researchers evaluate the link between organ transplant and the increased likelihood of developing diabetes.

Insurers have taken interest in outcomes-based contracts for specialty drugs and non-specialty drugs.

Portal hypertension can result in bleeding from varicose veins in the esophagus.

Greater education programming needed for patients at-risk for HIV infection.

The same gene that causes Chanarin-Dorfman syndrome could play a part in HCV.

Top news of the day from across the health care landscape.

Study finds need for updated pricing system for hepatitis C virus medications.

An experimental hepatitis C virus inhibitor was able to slow down the symptoms of Zika in mice.

Growing number of patients with life-threatening liver disease being removed from transplant waiting lists.

Long-term exposure to particulate matter increases mortality risk from cancer.

Liver tumors found to stop using fructose.

Acute exenatide administration reduces glucose production and insulin resistance in liver tissue.

Organ recipients with a history of cancer were 1.5 times more likely to die early from any cause compared with organ recipients without history of cancer.

Granulin implicated in the spread of cancer from the pancreas to the liver.

Novel HCV regimen shows high SVR12 rates at 8 and 12 weeks of treatment.

Dual transplant may have a protective role against cellular rejection.